Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst

Trial Title: Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst

NCT ID: NCT05696834

Condition: Orthopedic Disorder

Conditions: Official terms:
Bone Cysts
Bone Cysts, Aneurysmal
Musculoskeletal Diseases

Study type: Observational

Overall status: Active, not recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Procedure
Intervention name: Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
Description: Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
Arm group label: sclerotherapy and bone marrow

Summary: Aneurysmal bone cysts (ABCs) are benign, locally destructive growing bone tumors, which were first described in 1942 by Jaffé and Lichtenstein (1). They are most often diagnosed in childhood and early adulthood. The literature reports that ABCs comprise 1-6% of all primary benign bone tumors (2). Most cases of ABCs (75-90%) are reported for patients younger than 20 years, with a slightly higher incidence for females (3). Most common localizations are the pelvis, the metaphysis of long bones and the spine, but ABCs can also affect any other localization(2). ABCs that are associated with a preexisting osseous lesion are defined as secondary ABCs. They represent approximately 30% of all ABCs (2). Secondary ABCs can occur, e.g., in cases of a giant cell tumor, chondroblastoma or telangiectatic osteosarcoma

Detailed description: The clinical symptoms of an ABC are usually accidently discovered or may consist of pain and swelling in the affected region and pathological fractures ( complete and incomplete ) can be observed occasionally. In conventional radiography a relatively well-defined osteolytic, expansile lesion with possible blowout of the periosteum and a soap-bubble appearance can be found (4). MRI scanning shows cystic formations with typical fluid-fluid levels due to blood sedimentation (7). Because of the possible rapid growth with local destruction, the literature describes cases of ABCs that mimic malignant bone tumors

Criteria for eligibility:

Study pop:
20 Patients complaining from pain at all affected bones. All patients undergo to examination and investigated by radiological (Plain X-rays and MRI). All patients undergo to C-arm plain X-rays guided biopsy, aspirated histopathology, and Chemical study ( as Alkaline Phosphatase assessment ) as pre-operative planning. All patients received an injection of polidocanol intralesional as standard treatment with a dose: 2- 4 mg / Kg . Ossification ( healing ) was assessed on plain X-ray, and the pain was evaluated on a visual analog scale (VAS).

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - All Patients above age of 1 year. - The affected area was all bones except skull, ribs, and other non-orthopedic specialties. - Primary or recurrent ABC - Incomplete Fractured affected bones as greenstick fracture. - Healed Pathological fracture without any surgical intervention Exclusion Criteria: - ABC. In skull, ribs, and other non-orthopedic specialties. - Age less than 1 year - Suspected malignancy or other bone cysts - Complete fractured bones and healed pathological fracture with surgical intervention.

Gender: All

Minimum age: 1 Year

Maximum age: N/A

Locations:

Facility:
Name: Faculty of Medicine Al-Azhar University Assuit

Address:
City: Assuit
Country: Egypt

Start date: March 1, 2023

Completion date: December 2025

Lead sponsor:
Agency: Al-Azhar University
Agency class: Other

Source: Al-Azhar University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05696834